Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term VX-661 (tezacaftor) plus ivacaftor in cystic fibrosis with F508del mutation
2014-004827-29Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tezacaftor and ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoints: Long-term safety and tolerability and Long-term efficacy. Started Jul 2015; status: completed.
02
Drugs
tezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2014-004827-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004827-29.